M&A Deal Summary |
|
|---|---|
| Date | 2018-11-27 |
| Target | Jecure Therapeutics |
| Sector | Life Science |
| Buyer(s) | Genentech |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1976 |
| Sector | Life Science |
Genentech is a biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The Company is based in San Francisco.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Life Science M&A | 3 of 3 |
| Type: Add-on Acquisition M&A Deals | 3 of 3 |
| State: California M&A | 2 of 2 |
| Country: United States M&A | 3 of 3 |
| Year: 2018 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-07-01 |
Seragon Pharmaceuticals
San Diego, California, United States Founded in 2013, Seragon is focused on the development of selective estrogen receptor degraders (SERDs) for hormone receptor-driven cancers. SERDs are designed to bind the estrogen receptor and function as antagonists, and to induce conformational changes that may result in degradation of the receptor itself. |
Buy | $725M |
